All In Biotech

Drug Trial Radar · NCT05366478

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

A Single-Arm, Open-Label, Exploratory Study to Evaluate Safety and Efficacy of LM103 Injection in the Treatment of Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

May 30, 2022

Primary completion

May 30, 2024

Study completion May 30, 2029

Sponsor

Sponsor type
Industry
First posted
May 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.

Conditions

  • Melanoma
  • Non Small Cell Lung Cancer
  • Cervical Carcinoma

Interventions

  • Autologous tumor infiltrating lymphocytes (TILs)Drug

    A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients will be infused with LM103 Injection followed by IL-2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs)Time frame: Up to 1 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Beichen Hospital

    Tianjin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.